We used Revman 5 0 for the meta-analysis (Copenhagen: The Nordic

Results Table 1 shows the descriptive characteristics of the study participants. No significant differences

emerge when comparing cases and controls by age, race, education, and anthropometrics. Table 1 Participants Descriptive Characteristics by Case-Control Status, PROMEN Study, 1996-2001     Prostate Cancer     Control Case two-tails     n % n % p-value     110 80.88 26 19.12   Age   50-59 31 28.20 7 26.90     60-69 40 36.40 9 34.60     70-79 39 35.50 10 38.50               0,902 Race   Black 4 3.60 1       White 106 96.0 25                 1.000 Years of Education   8-13 66 60.00 16 MM-102 concentration 61.50     14-18 44 40.00 10 38.50               1.00 BMI   ≤ 25 25 22.90 6 23.10     25-30 55 50.50 11 42.30     ≥ 30 29 26.60 9 34.60               0.683 Waist circumference   ≤ 97,50 56 51.40 10 38.50     >

97,50 53 48.60 16 61.50               0.279 Hip circumference   ≤ 102,50 56 51.40 12 46.20     > 102,50 53 48.60 14 53.80               0.668 Waist to hip ratio   ≤ 0,95 55 50.50 14 56.00     > 0,95 54 49.50 11 44.00               0.662 *BMI: body mass index expressed as weight in kilograms divided by the square of height in meters (kg/m2) In Table 2, we report crude and age-adjusted Pca risk Epacadostat in vivo learn more Estimates in relation to tertiles of urinary estrogen metabolites and their ratio. The OR in the highest compared to the lowest tertile of 2-OHE1 was 0.72 (95% CI 0.25-2.10). Conversely, the odds in the highest tertile of 16α-OHE1 was 1.76 (95% CI 0.62-4.98). Finally, the 2-OHE1 to 16α-OHE1 ratio showed a non-significant risk reduction across tertiles (OR 0.56, 95% CI 0.19-1.68, in the highest tertile). When we tested the independent variables of interest for significance the in trends of associations, none of the models produced significant results.

Table 2 Crude and Adjusted Prostate Cancer Risk Estimates       Cs/Coa Crude ORb 95% CIc Adjusted ORd 95% CIc 2OHE1   1st tertile ≤ 0.21 10/37 1 – - –   2nd tertile 0.21 – 2.26 9/37 0.90 0.33 -2.47 0.90 0.32-2.46   3rd tertile > 2.26 7/36 0.72 0.25 -2.10 0.69 0.23-2.03   trend     0.85 0.50-1.44 0.83 0.49-1.42   P for trend     0.55   0.50   16OHE1   1st tertile ≤ 61.84 7/37 1 – - –   2nd tertile 61.84 – 158.74 7/37 1.00 0.32 – 3.13 1.00 0.32-3.13   3rd tertile >158.74 12/36 1.76 0.62 – 4.98 1.73 0.58-5.14   trend     1.35 0.80-2.30 1.33 0.76-2.33   P for trend     0.26   0.31   2OHE1/16OHE1   1st tertile ≤ 0,31 11/37 1 –   –   2nd tertile 0.31-1.64 9/37 0.82 0.30-2.21 0.80 0.30-2.17   3rd tertile > 1.64 6/36 0.56 0.19 – 1.68 0.57 0.19-1.71   trend     0.75 0.44-1.29 0.76 0.44-1.30   P for trend     0.30   0.

This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>